Varlilumab is a monoclonal antibody designed for immunotherapy of solid tumors and hematologic malignancies; it acts as an anti-CD27 antibody that activates T cells; it has been evaluated in a phase 1b clinical trial in combination with ONT-10 for advanced breast or ovarian cancer; it has also been studied in a phase 1/2 trial in combination with anti-PD-1 nivolumab for advanced refractory solid tumors.